Abstract
The therapeutic use of cells from healthy donors or patients is increasing. Decades ago, transfusion medicine and bone marrow transplantation provided the first successful cell therapeutics and established the foundations for cell delivery. Clinical investigation soon uncovered the double-edged facets of some cell products, which, for example, could correct anemia but also cause alloimmunization or eradicate minimal residual leukemia while inducing potentially lethal graft-versus-host disease (GVHD).1 Cell therapies have acquired a new dimension during the past 15 years with the emergence of engineered cells that are directed to differentiate toward a particular function, are genetically modified, or are reprogrammed before . . .
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have